UCLA Endocrinology

[ Home ] [ Up ] [ Contents ] [ Forms ]

Full list of publications  

 

RESEARCH PAPERS

RESEARCH PAPERS – PEER REVEIWED

  1. Boonjaren S, Stein J, Baehler HR, Osgood RW, Hsueh WA, Cohen S, Yashon D, and Ferris T. Effect of plasma sodium concentration on diluting segment sodium reabsorption. Kidney Int. 5:1-10, 1974.
  2. Johnson KR, Hsueh WA, Glusman SM, and Arnett FC. Fibrous myopathy: A rheumatic complication of drug abuse. Arthritis and Rheumatism 49:923-926, 1976.
  3. Hsueh WA, and Hsu TH. Thyrotoxicosis in a patient with secondary hypothyroidism. Southern Medical Journal 71:1174-1177, 1978.
  4. Hsueh WA, Luetscher JA, Carlson E, and Grislis G. Big renin in plasma of normal subjects on high-sodium intake. Lancet I:1281-1284, 1978.
  5. Hsueh WA, Hsu TH, and Federman DD. Endocrine features of Klinefelter’s syndrome. Medicine 57:447-461, 1978.
  6. Hsueh WA, Luetscher JA, Carlson E, Grislis G, Elbaum D, and Chavarri M. A comparison of cold and acid activation of big renin and of inactive renin in normal plasma. J. Clin. Endocrinol. Metab. 47:792-799, 1978.
  7. Zager PG, Luetscher JA, Hsueh WA, Chavarri MR, and Dowdy AJ. Adrenocorticaotropin-stimulated secretion of aldosterone and cortisol computed from plasma and red blood cell measurements. J. Clin. Endocrinol. Metab. 48:441-450, 1979.
  8. Hsueh WA, Paz-Guevara A, and Bledsoe T. Studies comparing the metabolic clearance rate of 11b , 17, 21-trihydroxypregn-1, 4-diene-3, 20-dione (prednisone) after oral 17, 21-dihydroxypregen-1, 4-diene-3, 11, 20-trione and intravenous prednisolone. J. Clin. Endocrinol. Metab. 48:748-752, 1979.
  9. Zager PG, Hsueh WA, and Luetscher JA. Effects of des-ASP’and-angiotensin II on secretion and metabolism of aldosterone. J. Clin. Endocrinol. Metab. 50:874-878, 1980.
  10. Hsueh WA, Carlson EJ, Luetscher JA, and Grislis G. Activation and characterization of inactive big renin in plasma of patients with diabetic nephropathy and unusual active renin. J. Clin. Endocrinol. Metab. 51:535-542, 1980.
  11. Hsueh WA, Luetscher JA, Carlson EJ and Grislis G. Inactive renin of high molecular weight (big renin) in normal human plasma. Hypertension 2:750-756, 1980.
  12. Hsueh WA, Carlson EJ, O’Connor EJ, and Warren S. Renin requires a structural alteration prior to its activation by kallikrein. J. Clin. Endocrinol. Metab. 51:942-944, 1980.
  13. Hsueh WA, Carlson EJ and Israel-Hagman M. Mechanism of acid-activation of renin: role of kallikrein in renin activation. Hypetension 3:Supple I, I-22, I-29, 1981.
  14. Hahn JA, Zipser RD, Stone RA, Zia PK, Hsueh WA, and Horton R. Studies of the renal vasoactive systems in hyproreninemic hypoaldosteronism. Prostaglandins and Medicine 6:549-556, 1981.
  15. Hsueh WA, Inactive renin in human plasma – Is it prorenin. Min. Elect. Metab. 7:169-178, 1982.
  16. Hsueh WA, Leutscher JA, Carlson EJ, Grislis G, McHargue A, and Fraze E. Changes in active and inactive renin in pregnancy. J. Clin. Endocrinol. Metab. 54:1010-1016, 1982.
  17. Hsueh WA, Goldstone R, Carlson EJ, and Horton R. Acute reduction in inactive renin during stimulation of active renin secretion by converting enzyme inhibition in man. 63:175s-177s, 1982.
  18. Hsueh WA, and Carlson EJ. Biochemical characterization of inactive renin from kidney and from several plasma sources. Clin. and Exp. Hypertension A4(11 and 12), 2027-2038, 1982.
  19. Goldstone R, Hsueh WA, Carlson EJ, and Horton R. Reciprocal changes in active and inactive renin after converting enzyme inhibition in normal man. J. Clin. Endocrinol. Metab. 56:264-268, 1983.
  20. Hsueh WA, Components of the renin-angiotensin system: an update: Am. J. Nephrology 3:109-118, 1983.
  21. Hsueh WA, Diabetes mellitus, moderate renal insufficiency and hyperkalemia. Am. J. Nephrology 3:233-240, 1983.
  22. Hsueh WA, Carlson EJ, and Dzau V. Characterization of inactive renin from human kidney and plasma: Evidence for a renal source of circulating inactive renin. J. Clin. Invest. 71:506-517, 1983.
  23. Stern N. Beck FWJ, Sowers JR, Tuck M, Hsueh WA, and Zipser RD. Plasma corticoids and hyperreninemic hypoaldosteronism: Evidence of diffuse impairment of the zona glomerulosa. J. Clin. Endocrinol. Metab. 57:217-220, 1983.
  24. Hsueh WA. Proteases in hormone production and metabolism. Adv. Exp. Biol. Med. 167:141-153, 1984.
  25. Hsueh WA, Potential role of renin activation in renin secretion. Am. J. Physiol. 7:F205-F212, 1984.
  26. Nadler JL, Hsueh WA and Horton R. Therapeutic effect of calcium blockade in primary aldosteronism J. Clin. Endocrinol. Metab. 60:896-899, 1985.
  27. Licht JA and Hsueh WA. Pseudohypoaldosteronism, type II: Renin angiotensin system and acid-base disturbances. Quart. J. Med. 54:161-176, 1985.
  28. Hsueh WA, Goldstone R. and Horton R. Evidence that the beta-adrenergic system and prostaglandins stimulate renin release through different mechanisms. J. Clin. Endocrinol. Metab. 61:399-403, 1985.
  29. Elkayam U, Roth A, Weber L, Hsueh WA, Nanna M, Freidenber L, and Rahimtoola S. Isometric exercise in chronic advanced heart failure: Hemodynamic and Neuro-humoral evaluation. Circulation 72:975-981, 1985.
  30. Elkalyam U, Roth A, Weber L, Hsueh WA, Nanna M, Freidenber L, and Rahimtoola SH. Changes in catechnloamies, renin and adosterone following therapy with hydralazine and nifedipine in severe heart failure: Amer. J. Cardiol. 111:1130-1138, 1986.
  31. Hsueh WA, New insights into the medical management of primary aldosteronism. Hypertension 8:76-82, 1986.
  32. Laffi G, Daskalopoulos G, Kronborg I, Hsueh WA, Gentilini P, and Zipser R. Effects of sunlindac and ibuprofen in patients with cirrhosis and ascites: An explanation for the renal-sparing effect of sulindac. Gastroenterology 90:182-187, 1986.
  33. Hsueh WA, Do Y, Shinagawa T, Tam H, Ponte P and Fritz L. Biochemical similarity of expressed human prorenin and native inactive renin. Hypertension 8(Suppl II), II-78-II-83, 1986.
  34. Nadler J, Lee FO, Hsueh WA and Horton R. Evidence for a prostacyclin deficiency in hyporeninemic hypoaldosteronism, N Engl J Med 314:1015-1020, 1986.
  35. Shinagawa T, Do YS, Tam H and Hsueh WA. Complete purification and amino terminal sequencing of human renal renin. Biochem Biophys Res Comm 139:446-454,
  36. Brar H, Do YS, Hsueh WA. The uteroplacental unit as a source of prorenin during pregnancy. Am. J. Obst. And Gyn. 155:1223-1226, 1986.
  37. Lee FO, Nadler JL, Hsueh WA. Effect of a synthetic prostacyclin analog on renin release in man. J. Hypertension 4(Suppl 5):S10-S13, 1986.
  38. Do YS, Shinagawa T, Tam H, Hsueh WA. Characterization of pure human renin: evidence for the substructure of human renal renin. J Biol Chem 262:103-107, 1987.
  39. Kulick DL, McIntosh N, Campese V, Hsueh WA. Rahimtoola SH, Griffith GC, Massry SG and Elkayam U. Central and renal hemodynamic effects in hormonal response to dilitiazem administration in severe congestive heart failure. Am. J. Cardiol. 59:1138-1143, 1987.
  40. Brar HS, Kjos SL, Doughtery W, Do YS, Tam HB and Hsueh WA. Increased fetal-placenta active renin production in pregnancy induced hypertension. Am. J. Obstet and Gynecol. 157:363-367, 1987.
  41. Elkayam U, Kulick D, McIntosh N, Roth A, Hsueh WA and Rahimtoola SH. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation 76:3:577-584, 1987.
  42. Lee FC, Quismorio FP, Jr, Troum OM, Anderson PW, Do YS and Hsueh WA. Mechanisms of hyperkalemia in systemic lupus erythematosus. Arch. Int. Med. 148:397-401, 1988.
  43. Do YS, Sherrod A, Lobo R, Paulson R, Shinagawa T, Chem S, Kjos S and Hsueh WA. Human ovarian theca cells are a source of renin. Proc. Nat. Acad. Sci. 75:1957-1961, 1988.
  44. Hsueh WA. Sexual dysfunction with aging and systemic hypertension. Am. J. Cardiology 61:184-23H, 1988.
  45. Hsueh WA, Luetscher JA, Carlson E and Grislis G. Big renin in plasma of normal subjects on high-sodium intake. Lancet I:1281-1284, 1978.
  46. Paulson R, Do YS, Hsueh WA and Lobo R. Gradients of prorenin and active renin in simutaneously obtained varian venous and peripheral venous blood. Am. J. Obstet. Gynecol. 159:1575-1759, 1988.
  47. Valenzuela GJ, Hewitt CW, Kramer GC, Do YS and Hsueh WA. Thoracic duet lymphatic function and cardiovascular effects after protein depletion via lymph drainage. Am. J. Physiol. 256:R867-R874, 1989.
  48. Paulson R, Do YS, Hsueh WA and Lobo R. Ovarian renin production in vitro and in vivo: characterization and clinical correlation. Fertil. and Steril. 51:634-638, 1989.
  49. Shaw KJ, Do YS, Kjos S, Anderson PW, Shinagawa T, Dubeau L and Hsueh WA. Human decidua is a major source of renin. J. Clin. Invest. 83:2085-2092, 1989.
  50. Anderson PW, Do YS, Schambelan M, Horton R, Boger RS, Luther RR and Hsueh WA. Effects of renin inhibition in systemic hypertension. Am. J. Cardiol. 66:1342-1347, 1990.
  51. Shinagawa T, Do YS, Baxter FD, Carilli C, Schilling J and Hsueh WA. Identification of an enzyme in human kidney that correctly processes prorenin. Proc. Nat. Acad. Sci. 87:1927-1931, 1990.
  52. Anderson PW, Macaulay L, Do YS, Sherrod A, D’Ablaing G, Koss M, Shinagawa TB, Montz FJ and Hsueh WA. Extrarenal renin-secreting tumors: insights into hypertension and ovarian renin production. Medicine 68:257-268, 1990.
  53. Anderson PW, Malarkey WB, Salk J, Kletsky OA and Hsueh WA. The effect of angiotensin-converting enzyme inhibition on prolactin responses in normal and hyperprolactinemic subjects. J. Clin. Endocrinol. Metab. 69:518-522, 1990.
  54. Hsueh WA and Baxter JA. Human Prorenin. Hypertension 17:469-479, 1991.
  55. Wang P-H, Do YS, Macauley LK, Shingawa T, Anderson PW, Baxter JD and Hsueh WA. Identification of renal cathepsin B as a human prorenin processing enzyme. J. Biol. Chem. 266:12633-12638, 1991.
  56. Buchanan TA, Sipos GF, Gadalah S, Yip K-P, Marsh DJ, Hsueh WA and Bergman R. Glucose tolerance and insulin action in rats with renovascular hypertension. Hypertension 18:341-34, 1991.
  57. Hsueh WA, Do YS and Wang P-H. Observations on the renal processing and sorting of prorenin. Can J Physiol Pharmacol 69:1327-1330, 1991.
  58. Hsueh WA, Do YS and Wang P-H. Processing and sorting human prorenin. Cell Biophysics 19:63-71, 1991.
  59. Hsueh WA. Effect of renin-angiotensin system in the vascular disease of type II diabetes mellitus. Am J Med 92(suppl 4B):13S-19S, 1992.
  60. Shinagawa T, Do YS, Baxter J and Hsueh WA. Purification of truncated prorenin. Biochemistry 31:2758-2764, 1992.
  61. Anderson P, Do YS and Hsueh WA. Angiotensin II causes mesangial cell hypertrophy. Hypertension 21:29-35, 1993.
  62. Buchanan TA, Thawani H, Kades W, Modrall JG, Weaver FA, Laurel C, Poppiti R, Xiang A and Hsueh WA. Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism. J Clin Invest 92:720-726, 1993.
  63. Anderson PW and Hsueh WA. Systemic hypertension and the renin-angiotensin system in diabetic vascular complications. Am J Cardiology. 72:14H-21H, 1993.
  64. Shotan A, Mehra A, Ostrzega E, Hsueh WA, Do YS, Fisher DA, Hurst A, Johnson JV and Elkayam U. Plasma cyclin guanosine monophosphate in chronic heart failure: hemodynamic and neurohormonal correlations and response to nitrate therapy. Clin Pharmacol Ther 54:638-643, 1993.
  65. Smith DL, Morris BJ, Do YS, Law RE, Shaw KJ and Hsueh WA. Identification of cyclic AMP response element in the human renin gene. Biochem Biophys Res Comm. 200:320-329, 1994.
  66. Morris BJ, Smith DL, Law RE, Do YS, Shaw KJ and Hsueh WA. Function of human renin proximal promoter DNA. Kidney Int. 46:1994.
  67. Smith DK, Law RE, Shaw KJ, Do YS, Hsueh WA and Morris BJ. Proximal 2.6kb of 5’-flanking DNA is insufficient for human renin promoter activity in renin-synthesizing chorio-decidual cells. Biochem Biophys Acta. 465-474, 1994.
  68. Wu H-Y, Jeng YY, Yue C-J, Chyu K-Y, Hsueh WA and Chan TM. Endothelial-dependent vascular effects of insulin and insulin-like growth factor-1 in the perfused rat mesenteric artery and artic ring. Diabetes 43:1027-1031, 1994.
  69. Morris RS, Francis MM, Do YS and Hsueh WA. Angiotensin II (AII) modulation of steroidogenesis by luteinized granulosa cells in vitro. J Asst Repro and Genetics, 11:(3) 117, 1994.
  70. Meehan WP, Buchanan TA and Hsueh WA. Chronic insulin administration elevates blood pressure in rats. Hypertension 23(part2):1012-1017, 1994.
  71. Buchanan TA, Meehan WP, Jeng YY, D Yang TM, Chan JL, Nadler JL, Scott, Rude RK and Hsueh WA. Blood pressure lowering by pioglitazone: Evidence for a direct vascular effect. J Clin Invest 96:354-360, 1995.
  72. Shinagawa T, Kazuhisa N, Uchiyama Y, Komaninami E, Doi Y, Hashiba K, Yano K, Hsueh WA, Murakami K. Prorenin processing enzymes in human kidney. Hypertension Research 18:131-136, 1995.
  73. Koichi I, Ashizawa N, Do YS, Graf K and Hsueh WA. Comparison of Angiotensin II with other growth factors on Egr-1 and matrix gene expression in cardiac fibroblasts. Am J Physiol. 270:H2100-H2107, 1996.
  74. Anderson PW, Zhang XZ, Tian J, Correale JM, Xi XP, Yang D, Graf K, Law RE and Hsueh WA. Insulin and angiotensin II are additive in stimulating TGF-b matrix mRNAs in mesangial cells. Kidney Int. 50:745-753, 1996.
  75. Hsueh WA, Law RE, Saad M, Dy J, Feener E, and King G. Insulin resistance and macrovascular disease. Current Opinion in Endocrinology and Diabetes 3:346-354, 1996.
  76. Law RE, Meehan WP, Xi XP, Graf K, Faxon D, Coats W, and Hsueh WA. Troglitazone inhibites vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 98:1897-1905, 1996.
  77. Ashizawa N, Graf K, Do YS, Nunihiro T, Giachelli CM, Meehan WP, Tuan T-L and Hsueh WA. Osteopontin is produced by rat cardiac fibroblasts and mediated AII-induced DNA synthesis and collagen gel contraction. J Clin Invest. 98:2218-2227, 1996.
  78. Graf K, Xi XP, Yang D, Fleck E, Hsueh WA and Law RE. Mitogen-activated protein kinase-activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 29:334-339, 1996.
  79. Graf K, Xi XP, Hsueh WA and Law RE. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells. FEBS Letters 400;119-121, 1997.
  80. Xi XP, Graf K, Goetze S, Hsueh WA and Law RE. Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk in vascular smooth muscle cells. FEBS Letters 417:283-286, 1997.
  81. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC, Fleck E and Hsueh WA. Myocardial osteopontin expression is associated with left ventricular hypertrophy. Circulation, 96:3063-3071, 1997.
  82. Hsueh WA, Law RE. Pharmacological treatment and mechanisms of insulin resistance: impact on vascular smooth muscle cells, blood pressure, and lipids. Annals NY Acad Sci, 827:170-177, 1997.
  83. Hsueh WA, Quinones MJ, Creager MA. Endothelium in insulin resistance and diabetes. Diabetes Reviews, 5:343-352, 1997.
  84. Nunohiro T, Ashizawa N, Graf K, Do YS, Hsueh WA, and Yano K. Angiotensin II promotes remodeling-related events in cardiac fibroblasts. Heart Vessels Suppl. 12: 201-204, 1997.
  85. Hinton DO, He S, Graf K, Yang D, Hsueh WA, Ryan SJ, and Law RE. Mitogen-activated protein kinase activation mediates PDGF-directed migration of RPE cells. Exper Cell Res, 239:11-15, 1998.
  86. Hsueh WA, Law RE. Cardiovascular Risk Continuum: Implications of insulin resistance and diabetes. Am J Med, 105(1A):4S-14S, 1998.
  87. Hsueh WA, Law RE, Do YS. Integrins, adhesion, and cardiac remodeling. Hypertension, 31:176-180, 1998.
  88. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, and Shulman GI. Metabolic effects of troglitzone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128(3):176-185, 1998.
  89. Xi X-P, Graf K, Goetze S, Fleck E, Hsueh WA, Law RE. Central Role of the MAPK pathway in AngII-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb. Vasc. Biol., 19:73-82, 1999.
  90. Goetze S, Xi X-P, Kawano H, Kawano Y, Fleck E, Hsueh WA, Law RE. TNFa -induced migration of vascular smooth muscle cells is MAPK-dependent. Hypertension, 33:183-189, 1999.

  91. Goetze S, Xi X-P, Kawano H, Gotlibowski T, Fleck E, Hsueh WA, Law RE. PPARg ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells.  J. Cardiovasc. Pharm., 33:798-806, 1999.

  92. Hsueh WA, and Law RE. Insulin signaling in the arterial wall. Amer J Cardiology, 84:21J-24J, 1999.

  1. Goetze S, Xi X-P, Graf K, Fleck E, Hsueh WA, Law RE. Troglitazone inhibits AII induced ERK 1 and 2 nuclear translocation and activation in vascular smooth muscle cells. FEBS Letters, 452:277-282, 1999.
  2. Jackson SM, Parhami F, Xi X-P, Berliner JA, Hsueh WA, Law RE, Demer LL. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol., 19:2094-2104, 1999.
  3. Kawano H, Do Y, Kawano Y, Starnes V, Barr M, Law RE, Hsueh WA. Angiotensin II has multiple profibrotic effects in human cardiac fibroblast. Circulation, 101:1130-1137, 2000.
  4. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Expression and function of PPARg in rat and human vascular smooth muscle cells. Circulation, 101:1311-1318, 2000.
  5. Kawano H, Cody RJ, Graf K, Goetze S, Kawano Y, Schnee J, Law RE, Hsueh WA. Angiotensin II enhances integrin and a -actinin expression in adult rat cardiac fibroblasts. Hypertension, 35:273-279, 2000.
  6. Graf K, Neuss M, Stawowy P, Hsueh WA, Fleck E, Law RE. Angiotensin II and alpha(v)beta(3) integrin expression in rat neonatal cardiac fibroblasts. Hypertension, 35:978-984, 2000.
  7. Kintscher U, Wakino S, Jackson SM, Fleck E, Hsueh WA, Law RE. Doxazosin inhibits retinoblastoma phosphorylation and G1® S transition in human coronary smooth muscle cells. Arterioscler Thromb Vasc Biol, 20:1216-1224, 2000.
  8. Goetze S, Kim S, Xi XP, Graf K, Yang DC, Fleck E, Meehan WP, Hsueh WA, Law RE. Troglitazone inhibits mitogenic signaling by insulin in vascular smooth muscle cells. J Cardiovasc Pharmacol, 35:749-757, 2000.
  9. Goetze S, Kintscher U, Kawano H, Kawano Y, Wakino S, Fleck E, Hsueh WA, Law RE. TNF-alpha inhibits insulin-induced mitogenic signaling in vascular smooth muscle cells. J Biol Chem, 275:18279-18283, 2000.
  10. Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE. Peroxisome proliferator activated receptor gamma ligands inhibit Rb phosphorylationand G1® S transition in vascular smooth muscle cells. J Biol Chem, 275:22435-22441, 2000.
  11. Murata T, He S, Hangai M, Ishibashi T, Xi X-P, Kim S, Hsueh WA, Ryan SJ, Law RE, Hinton DR. Peroxisome proliferator-activated receptor-g ligands inhibit choroidal neovascularization. Invest Opthamol Vis Sci, 41:2309-2317, 2000.

RESEARCH PAPERS - PEER REVIEWED (IN PRESS)

  1. Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RAS, Graf K, Fleck E, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharm, in press, 2000.

CHAPTERS

  1. Leutscher J.A., and W.A. Hsueh. Big renin: Inactive Renin of High Molecular Weight in Human Plasma. Endocrinology p. 174-178, 1980.
  2. W.A. Hsueh and E. J. Carlson. Reversible Activation of Plasma Inactive Renin. Heterogeneity of Renin and Renin Substrate. (M. Sambhi, ed.) Elsevoir North Holland, New York, p. 175-182, 1981.
  3. Bennet C.M. and W.A. Hsueh. Measurement of Renin and Interpretation of Plasma Renin Activity. (S. Massry, ed.) Textbook of Nephrology, Willams and Wilkins, Baltimore, 1983, updated, 1987.
  4. Horton R., and W.A. Hsueh. Treatment of Hyperaldosteronism. (D. Kreiger, C.W. Barden, eds.) Current Therapy in Endocrinology. p. 127-131, B.C. Denver, Inc. Philadelphia, 1983, updated 1987, 1993.
  5. Massry S., W.A. Hsueh, and E. Dunker. Metabolic and Endocrine Abnormalities in Acute Renal Failure. (S. Massry, ed.) Textbook of Nephrology, Williams and Wilkins, Baltimore, 1983 updated 1987,1993.
  6. W.A. Hsueh and M. Tuck. Aldosterone and the renin angiotensin system. (K. Becker, ed.) Principles and Practice of Endocrinology. J B Lippincott, Philadelphia, p. 623-631, 1990.
  7. Campese V.M., and W.A. Hsueh. Recent advances on the renal nervous system and prorenin in hypertension. Seminars in Nephrology, 1987.
  8. Baxter J.D., D. Perloff, and W.A. Hsueh. Endocrine Hypertension, Endocrinology ad, (eds., Felig, Baxter, Broadus, Fichman) McGraw-Hill, New York, 1987, p. 693-978, updated.
  9. W.A. Hsueh. Treatment of Pregnancy-Induced Hypertension. Current Therapy in Endocrinology and Metabolism (ed. C.W. Bardin) B.C. Decker Inc., Philadelphia p. 252-254, 1990, updated.
  10. W.A. Hsueh and M. Stallcup editors: Cellular mechanisms of protein processing and sorting. 1992.
  11. W.A. Hsueh. Insulin resistance and essential hypertension in Yearbook of Nephrology (ed Fine L., and Andreucci V.E.), Springer-Verlag, New York, p. 117-138, 1992.
  12. W.A. Hsueh and Anderson P.W. Prorenin and the Renin-Angiotensin System in Diabetic Nephropathy. Seminars in Nephrology, 13:573-580, 1993.
  13. Anderson P.W., W.A. Hsueh. Hypertension and Diabetic Vascular Complications. Recent Advances in Internal Medicine, 39:633-665, 1994.
  14. Saad M.F., Tubau J., W.A. Hsueh. Cardiovascular manifestations of diabetes in Cardiology and Co-existing disease (ed. E. Rapaport), Churchill Livingstone, NY, 1994, p. 107-174.

REVIEWS

  1. Baxter JD, Duncan K, Chu W, James MNG, Russell RB, Haidar M, DeNoto FM, Hsueh WA and Reudelhuber TL. Molecular biology of human renin and its gene. Recent Prog Hor Res. 47:211-257, 1991.
  2. Hsueh WA and Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension 20:253-263, 1992.
  3. Hsueh WA. Role of the extrarenal renin-angiotensin system. Current Science 7:745-751, 1992.
  4. Hsueh WA. Insulin Resistance and Hypertension. Am J Nephrol 11:265-270, 1992.
  5. Hsueh WA and Buchanan TA. Obesity and Hypertension. Endo Clinics N Am 23:405-427, 1994.
  6. Hsueh WA, Law RE, Saad M, Dy J, Feener E and King G. Insulin resistance and macrovascular disease. Current Opinion in Endocrinology and Diabetes 3:346-354, 1996.
  7. Hsueh WA, and Law RE. Pharmacological treatment and mechanisms of insulin resistance: impact on vascular smooth muscle cells, blood pressure and lipids. Ann NY Acad Sci 827:170-177, 1997.
  8. Hsueh WA, Law RE and Do YS. Integrins, adhesion and cardiac remodeling. Hypertension 31:176-180, 1998.
  9. Hsueh WA. Complicated hypertensive patients: Diabetes and insulin resistance. Postgraduate Medicine Special Report, "Individualization of treatment for hypertension in 1998. Pgs. 11-16, 1998.
 

 

[ Home ] [ Up ]